Questions about Keleutha
What is Keleutha?
Keleutha is a pre-clinical research and development company developing whole-genome newborn screening for rare genetic disorders. It aims to expand on the standard heel-prick test by reading the entire genome from a single sample and reporting a small number of clinically relevant findings. The service is currently in a research stage and not yet a clinical test, with results filtered to a curated list of conditions.
How do I get started or inquire about the service?
The company states that inquiring does not enroll you in anything and does not book a test immediately. Instead, users are asked to sign up once and provide an email address to receive updates on how the screen is coming along and when enrollment opens near them. This process is described as a way to keep families informed without committing to a test right away.
What is the process for screening and follow-up?
Keleutha claims to read a newborn's whole genome once, explain it in plain words, and connect families with the same rare gene. The company also mentions that genetic counselors would follow up with families to discuss any uncertain findings, though this is part of their planned process rather than a completed service.
What statistics does Keleutha use to justify its approach?
The company highlights that 4% of newborns screen positive for a treatable condition, citing a source stating 3.7% of 4,000 newborns screened for 156 early-onset conditions had positive results. They also note that more than 9 in 10 people carry at least one actionable pharmacogenomic variant, based on a study from 2016.
How does Keleutha expand its screening capabilities?
Keleutha mentions that its panel is continuously expanding and includes testing for polygenic predispositions to add crucial early insights. They state that more conditions mean more clarity and that they leave no gene unread when it matters most, emphasizing their commitment to comprehensive screening.
What is the primary goal of Keleutha's screening technology?
Keleutha states that they aim to shorten every medical odyssey by providing early insights through whole-genome screening. They believe that testing for polygenic predispositions adds crucial early insights, helping to identify potential health risks sooner.
What is Keleutha's commitment to thoroughness in screening?
The company highlights that they leave no gene unread when it matters most, emphasizing their commitment to comprehensive and thorough screening. This approach is designed to ensure that no potential health issue is overlooked during the screening process.
How does Keleutha ensure that families understand the results?
The company states that they will explain results in plain words, ensuring that families can understand the implications of the screening. This approach is designed to make complex genetic information accessible and understandable to non-experts.
What is the official website of Keleutha?
The official website of Keleutha is keleutha.com.
Does Keleutha have reviews on Trustburn?
Keleutha has no reviews on Trustburn yet. Anyone who has used it can write the first review on its Trustburn page.
Post your question publicly — other visitors, and whoever manages this page, can answer. It will be visible on this page.
Want to hear about this company again? Follow it and we’ll email you when a new review appears.
Based on reviews, listing data and the company's website. Verify anything important with the company directly.
Questions & Answers
Is this whole-genome screening service suitable for families who want immediate, definitive clinical diagnosis rather than research-level data?
Trustburn Team suggests a starter question on new profiles — the business hasn’t answered yet.
Sign in to post
Your text is saved — you'll come right back to post.
Don't have an account? Create one
News & Press
No news yet. This is where the business shares its own updates and press.
About Keleutha
Keleutha is a company developing whole-genome newborn screening for rare genetic disorders. It aims to expand on the standard heel-prick test by reading the entire genome from a single sample and reporting a small number of clinically relevant findings. The service is described as being in a research stage and not yet a clinical test, with results filtered to a curated list of conditions. The company also indicates that genetic counselors would follow up with families to discuss any uncertain findings.
- Website
- keleutha.com
- [email protected]
- Categories
- Research, Biotechnology

